What does Taysha Gene Therapies, Inc. do?

Jun 22 2025 07:20 PM IST
share
Share Via
Taysha Gene Therapies, Inc. develops adeno-associated virus-based gene therapies for monogenic diseases of the central nervous system. As of March 2025, it has a market cap of $666.90 million, with net sales of $2 million and a net loss of $22 million.
Overview:
Taysha Gene Therapies, Inc. is a gene therapy company focused on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system, operating in the Pharmaceuticals & Biotechnology industry with a micro-cap market capitalization.

Financial Snapshot:
Most recent Net Sales: 2 Million (Quarterly Results - Mar 2025)
Most recent Net Profit: -22 Million (Quarterly Results - Mar 2025)
Market cap: USD 666.90 Million (Micro Cap)

Key Metrics:
P/E: NA (Loss Making)
Industry P/E: NA
Dividend Yield: 0.00%
Debt Equity: -1.31
Return on Equity: -149.22%
Price to Book: 12.11

Contact Details:
Address: 2280 Inwood Road, DALLAS TX: 75235
Tel: 1 214 6120000
Website: https://tayshagtx.com/
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News